Presentation

W1.3 Design of self-assembling protein nanomaterials as next.generation vaccine scaffolds

Neil King

Workshop presentation

Authors

Languages

  • English

Publication year

2016

Type

Presentation

Categories

GVIRF-2016

This resource appears in the following Hot Topic page:

The resource is included in the following table:

TitleAuthorYearTypeLanguage
*Meeting report: Global vaccine and immunization research forumAndrew Ford, Angela Hwang, B. Fenton Hall, Joachim Hombach, Nancy Touchette2018Journal articleEnglish
Context and Purpose of GVIRFThomas Cherian2016ReportEnglish
KN1 Opening Session and Dr Margaret Chan KeynoteGVIRF Secretariat2016ReportEnglish
KN3 Vaccine Manufacturing in Africa: Self-sufficiency, a need? Or a dream?William Ampofo2016PresentationEnglish
P1.1a RSA & HIV vaccine efficacy studiesGlenda Gray2016PresentationEnglish
P1.1b HIV Vaccines: Marry HIV efficacy studies to science, but take shots on goalNelson Michael2016PresentationEnglish
P1.2a TB Vaccine Research and Development: Progress, Strategies and ControversiesLewis Schrager2016PresentationEnglish
P1.3a Malaria VaccinesEusebio Macete2016PresentationEnglish
P1.3b Vaccines for Malaria - Updates on ProgressMahamadou Thera2016PresentationEnglish
P2 The role of moderate efficacy vaccines in integrated disease control strategiesKatherine L. O'Brien2016ReportEnglish
P2.1 The role of moderate efficacy vaccines in integrated disease control strategies: IntroductionKathleen Neuzil2016PresentationEnglish
P2.2 Lessons from Rotavirus and Pneumococcal Conjugate VaccinesKatherine L. O'Brien2016PresentationEnglish
P2.3 Moderate efficacy malaria vaccines as part of comprehensive malaria control and eliminationSalim Abdullah2016PresentationEnglish
P2.4 Reflections on the use of future HIV vaccines as part of an integrated package of preventive measuresWalter Jaoko2016PresentationEnglish
P3 Evolving Global Vaccine MarketsAmie Batson2020ReportEnglish
P3.1 Global vaccine marketAmie Batson2016PresentationEnglish
P4 Preparing for the next Infectious Disease EmergencyHelen Rees, Norman BaylorReportEnglish
P4.1 Preparing for the inevitableDavid Wook2016PresentationEnglish
P4.2 Preparing for the Next Infectious Disease EmergencyLucille Blumberg2016PresentationEnglish
P4.3 Regulatory Preparedness for the Next Infectious Disease EmergencyDelese Mimi Darko2016PresentationEnglish
P5 New Technologies to Support Measles EliminationA. A. Adeyemo2016ReportEnglish
P5.1 What are the measles vaccination coverage gaps?Peter Strebel2016PresentationEnglish
P5.2 The Investment Case for Measles EradicationKimberly Thompson2016PresentationEnglish
P5.3 Measles and Rubella Research AgendaNarendra K Arora2016PresentationEnglish
P5.4 An emerging vaccine delivery technology for measles and rubella eliminationJames Goodson2016PresentationEnglish
P6.1 Universal Influenza Vaccine DevelopmentBarney S. Graham2016PresentationEnglish
P6.2 Vaccine development for Group A StreptococcusAndrew Steer2016PresentationEnglish
P6.3 Schistosomiasis Vaccine UpdatesAnnie Mo2016PresentationEnglish
P6.4 Preferred Product CharacteristicsDavid Kaslow2016PresentationEnglish
W1.0 Introduction: Applying Novel Technologies to Vaccine DevelopmentRino Rappuoli2016PresentationEnglish
W1.1 Structural studies of viral envelope proteins and insights for vaccine designFelix Rey2016PresentationEnglish
W1.2 Epitope-focused vaccine designBill Schief2016PresentationEnglish
W1.3 Design of self-assembling protein nanomaterials as next.generation vaccine scaffoldsNeil King2016PresentationEnglish
W10.1 Monoclonal antibodies for infectious diseasesMartin Friede2016PresentationEnglish
W10.2 Passive vaccination as a global strategy for preventing RSV disease in infantsFilip Dubovsky2016PresentationEnglish
W10.3 Gene-based Delivery of Broadly Neutralizing Antibodies for HIV PreventionWayne Koff2016PresentationEnglish
W10.4 Rabies antibodies for Passive Post-exposure prophylaxisTsepo Tsekoa2016PresentationEnglish
W11 Vaccine HesitancyNarendra Arora2016ReportEnglish
W11.1 Vaccine Hesitancy: what it means and what we need to know in order to tackle itRobb Butler2016PresentationEnglish
W11.2 Vaccine Hesitancy: Determining the scale of the challengeSusan Goldstein2016PresentationEnglish
W11.3 Tailoring Immunization Programmes (TIP): An example of tailoring communication on vaccinations targeting hard.to.serve communities in SwedenAnn Lindstrand2016PresentationEnglish
W11.4 Applying TIP to low and middle income settings: a case study from South AfricaNicola Christofides and Janine Simon-Meyer2016PresentationEnglish
W2 Comprehensive assessment of risks and benefits of vaccines: the example of DengueLucky Slamet, Stephen Thomas2023ReportEnglish
W2.2 Public Health Criteria for Dengue Vaccine Risk/Benefit Assessment and Risk ManagementPeter Smith2016PresentationEnglish
W3 Total Systems EffectivenessCarsten Mantel, Darin Zehrung, James Goodson, Jean-Pierre Amorij, Melissa Malhame, Mercy Mvundura, Messeret Shibeshi, Tina Lorenson2016ReportEnglish
W3.1 Introduction: Total Systems EffectivenessTina Lorenson2016PresentationEnglish
W3.2 Total System EffectivenessTina Lorenson2016PresentationEnglish
W3.3 Microarray patch case study: Measles-rubella vaccineDarin Zehrung2016PresentationEnglish
W3.4 Vaccine technology costs and health impact assessment toolMercy Mvundura2016PresentationEnglish
W4.1 Introduction: Antimicrobial Resistance & VaccinesA. A. Adeyemo2016PresentationEnglish
Log in to vote

Added by: Angela Hwang

Added on: 2022-08-06 11:15:53

Hits: 1595

Uploaded file

W1-3King.pdf

Click to Download

Report an issue

Add resource